{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T23:50:23Z","timestamp":1778975423877,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Handok, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the efficacy of an endothelin receptor antagonist (ERA) and phosphodiesterase type5 inhibitors (PDE5is) for treating SSc-related digital ulcers (DUs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This prospective, multicentre, observational cohort study recruited patients with active SSc-related DUs from 13 medical centres in South Korea. The primary outcome was time to cardinal ulcer (CU) healing. A secondary outcome was time to new DU occurrence. Patients were followed up 4, 8, 12 and 24\u2009weeks after treatment initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-three patients were analysed. Their mean age was 49.9 years (s.d. 11.4) and 49 were female. Twenty-eight had limited SSc. Forty-nine patients received ERA, 11 received a PDE5i (9 sildenafil, 1 udenafil and 1 tadalafil) and 3 received other medication. The hazard ratio (HR) for time to CU healing in the ERA group vs the PDE5i group was 0.75 (95% CI 0.35, 1.64; P\u2009=\u20090.47) in an unadjusted model and 0.80 (95% CI 0.36, 1.78; P\u2009=\u20090.59) in a model adjusted for age, sex, use of calcium channel blockers (CCBs), total DU number and initial CU area. The HR for new DU development in the ERA group vs the PDE5i group was 0.39 (95% CI 0.16, 0.93; P\u2009=\u20090.03) in an unadjusted model and 0.32 (95% CI 0.13, 0.81; P\u2009=\u20090.02) in an adjusted model. No patients receiving CCBs developed new DUs at 24\u2009weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Time to CU healing is comparable for ERA and PDE5i. ERAs are more effective in reducing new DU occurrence than PDE5is. CCBs may be effective as a background medication.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab147","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T14:33:00Z","timestamp":1612881180000},"page":"5814-5819","source":"Crossref","is-referenced-by-count":8,"title":["A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-7194","authenticated-orcid":false,"given":"Sung Hae","family":"Chang","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Bum","family":"Jun","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Young","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki Won","family":"Moon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyeon","family":"Ju","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary\u2019s Hospital, Catholic University of Korea, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Wook","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Ah","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Geun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Busan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-7355","authenticated-orcid":false,"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam Hun","family":"Heo","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, Soonchunhyang University Cheonan Hospital, Cheonan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-1208","authenticated-orcid":false,"given":"Eun Bong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul"},{"name":"Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"2021121823175787000_keab147-B1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2021121823175787000_keab147-B2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021121823175787000_keab147-B3","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"2021121823175787000_keab147-B4","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021121823175787000_keab147-B5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021121823175787000_keab147-B6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"2021121823175787000_keab147-B7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021121823175787000_keab147-B8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5301\/jsrd.5000232","article-title":"Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up","volume":"2","author":"Seibold","year":"2017","journal-title":"J Scleroder Relat Disord"},{"key":"2021121823175787000_keab147-B9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"2021121823175787000_keab147-B10","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021121823175787000_keab147-B11","doi-asserted-by":"crossref","first-page":"E922","DOI":"10.1152\/ajpendo.00078.2013","article-title":"Title efficacy of phosphodiesterase 5 inhibitor on distant burn-induced muscle autophagy, microcirculation, and survival rate","volume":"304","author":"Hosokawa","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2021121823175787000_keab147-B12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.18433\/J3TC7V","article-title":"An old drug for a new application: potential benefits of sildenafil in wound healing","volume":"15","author":"Farsaie","year":"2012","journal-title":"J Pharm Pharm Sci"},{"key":"2021121823175787000_keab147-B13","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-\u03b2 and may be blocked by macitentan, a dual endothelin-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J Rheumatol"},{"key":"2021121823175787000_keab147-B14","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1122-y","article-title":"Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study","volume":"18","author":"Corallo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021121823175787000_keab147-B15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/2397198318823951","article-title":"Management of Raynaud\u2019s phenomenon in systemic sclerosis\u2014a practical approach","volume":"4","author":"Fern\u00e1ndez-Codina","year":"2019","journal-title":"J Scleroder Relat Disord"},{"key":"2021121823175787000_keab147-B16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud\u2019s phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2021121823175787000_keab147-B17","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2021121823175787000_keab147-B18","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/ket417","article-title":"Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study","volume":"53","author":"Lee","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2021121823175787000_keab147-B19","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","article-title":"Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study","volume":"298","author":"Rademaker","year":"1989","journal-title":"BMJ"},{"key":"2021121823175787000_keab147-B20","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab147\/36635136\/keab147.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/12\/5814\/41820430\/keab147.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/12\/5814\/41820430\/keab147.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:25:11Z","timestamp":1639869911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/12\/5814\/6134108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,2,12]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab147","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,2,12]]}}}